Barclays raised the firm’s price target on Veeva to $227 from $225 and keeps an Overweight rating on the shares. The company’s beat billings estimates, driven by timing of deals, but now the fiscal year billings are growing consistently 14%-16% versus prior second half of 2023 ramp fears, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on VEEV:
- Veeva Systems (NYSE:VEEV): Here’s How Analysts Reacted to the Stock After Q2 Results
- Veeva price target raised to $220 from $200 at BofA
- Veeva price target raised to $211 from $205 at Stifel
- Veeva price target raised to $240 from $210 at Raymond James
- Veeva price target raised to $235 from $232 at Piper Sandler